A new frontier in gynecologic disease detection.

MDDx is building the first diagnostic platform that detects gynecologic cancers and chronic conditions early, at their site of origin, when treatment is most effective and lives can be saved.

Learn more

Early detection saves lives

Routine screening has transformed outcomes for many cancers. But for ovarian and endometrial cancer, there is still no reliable early detection test. Most cases are found late, when treatment is hardest and outcomes are worst.Chronic conditions like endometriosis can take years to diagnose, leaving millions of women without answers.

Phase 1 - Cancer

Most ovarian cancers are detected too late

17–45% survival when caught late

Detection at the site  of origin

>90% survival with early detection

Phase 2 - Chronic Disease

Chronic gynecologic  
conditions take years to diagnose

7+ year diagnostic delay.Pain, infertility, repeated procedures

Early, objective  detection at the source

Faster diagnosis Improved care decisions
Reduced cost and burden

One platform. Multiple diseases. Earlier, clearer answers.

How MDDx works

Unlike blood tests that wait for distant signals, MDDx goes directly to the biological source. A simple sample collected during a routine visit reveals what blood tests miss.

STEP 1

Collect

A small sample is collected during a routine OB/GYN visit — just like a Pap smear. No extra appointments, no special equipment.

STEP 2

Analyze

Our platform isolates molecular signals from the source tissue and applies advanced ML to detect disease patterns invisible to traditional tests.

STEP 3

Act

The doctor receives a clear, actionable risk report — enabling earlier treatment decisions when they matter most.

Our Science

Built on over a decade of pioneering work in gynecologic disease detection — spanning early genomic discovery, uterine lavage sampling, and now proteomic, machine learning–driven diagnostics.

Foundational Work

Establishing the biological basis for early detection, including initial demonstrations that uterine lavage captures disease signals prior to conventional diagnosis.

Translational Expansion

Linking lavage-derived signals to tumor biology through large-scale genomic and proteogenomic efforts.

Platform Development

Integration of EV proteomics with proprietary machine learning models, enabling multi-pathway detection and orthogonal validation.

Clinical Validation & Deployment

Multi-institutional validation across cancer and chronic conditions, supported by NIH funding and presented at leading scientific andclinical meetings.

35K+

clinically annotated
samples

1,200+

validated acrossmulti-institutional cohorts

>90%

sensitivity &
specificity

NIH

multiple SBIR - 
funded programs

Peer-reviewed presentations at leading scientific and clinical meetings:

The results speak
‍for themselves

Validated across 1,200+ patient samples at leading medical centers.

>90%

early-stage detection for ovarian & endometrial cancers

(vs. 16–50% with current tests)

>95%

detection accuracy for endometriosis & fibroids

90%

survival rate when cancer  is caught early

(vs. 17% when caught late)

10x

reduction in treatment costs

($500K → $50K)

Who MDDx is for

Healthcare Partners

Integrate early detection into your OB/GYN workflow with no new equipment or training. Our test fits seamlessly into existing Pap smear visits.

Learn more

Health Systems

Offer your patients a diagnostic that catches disease earlier, reduces downstream costs, and positions your institution at the forefront of women's health.

Learn more